Cysteamine Bitartrate Global Patent Coverage & Expiry Overview

Track protection status across key markets to assess launch feasibility.

Start your free 7-Day Trial! Book a demo to explore our global patent data.

It is formulated by 1 pharmaceutical company such as HORIZON. It is marketed under 1 brand name, including PROCYSBI. Available in 4 different strengths, such as EQ 25MG BASE, EQ 75MG BASE, EQ 75MG BASE/PACKET and others, and administered through 2 routes including CAPSULE, DELAYED RELEASE;ORAL, GRANULE, DELAYED RELEASE;ORAL.

Strategic Dashboard

info

insightsStrategic Insights

Sourcing & Feasibility

check_circle API availability: autorenew Loading API feasibility...

groups Licensing: 1 potential partners

calendar_todayUS Launch window: autorenew Loading launch window...

timeline Key Patent Barrier & Expiry Timeline

autorenew Loading patent barriers...

factoryGeneric Manufacturer Snapshot

autorenew Loading manufacturers...

gavelRisk & Opportunity Summary

dangerous Risk: autorenew Loading risk analysis...
watch_later Watch: autorenew Loading watch analysis...
rocket_launch Opportunity: autorenew Loading opportunity analysis...
flag
gavel
calendar_today
calendar_today

Access Global Patent Data

Stay ahead with worldwide patent expiry and latest updates.

✓ Comprehensive global patent expiry timelines
✓ Full patent family details and status updates
Unlock Global Patents

Orange Book Drug Approval Timeline

FDA approval history for this ingredient

NDA (New Drug Application) ANDA (Generic Application)

Access Global Exclusivity and Patent Expiry Extensions

Stay ahead with worldwide patent expiry insights, exclusivity data, and latest updates.

✓ Comprehensive global patent expiry timelines
✓ Full patent family details and status updates
✓ Latest exclusivity data and extensions
Unlock Global Access

US Orange Book Patents Expiration Timeline

Key expiration dates for US patents covering this ingredient

View Global Patents Expiration Timeline

Stay ahead with worldwide patent expiry insights, market data, and research updates.

✓ Comprehensive global patent expiry timelines
✓ Full patent family details and status updates
Unlock Global Patent Timeline

Orange Book Drug Strengths

Latest drug strengths approved by FDA

Strength Route of Administration Companies Latest Approval Date

Orange Book Patents

Patents approved by the FDA for the ingredient

Patent Number Publication Date Legal Status Patent Expiry Date
{"application_id":"43942","ingredient":"CYSTEAMINE BITARTRATE","trade_name":"PROCYSBI","family_id":"8d5dc6df320241e2b2bc","publication_number":"US9925158B2","cleaned_patent_number":"9925158","drug_product_flag":"-, Y","drug_substance_flag":"-, Y","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2027-07-26","publication_date":"2018-03-27","legal_status":"Granted"} US9925158B2 27 Mar, 2018 Granted 26 Jul, 2027
{"application_id":"43935","ingredient":"CYSTEAMINE BITARTRATE","trade_name":"PROCYSBI","family_id":"8d5dc6df320241e2b2bc","publication_number":"US9192590B2","cleaned_patent_number":"9192590","drug_product_flag":"-","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2027-07-26","publication_date":"2015-11-24","legal_status":"Granted"} US9192590B2 24 Nov, 2015 Granted 26 Jul, 2027
{"application_id":"43907","ingredient":"CYSTEAMINE BITARTRATE","trade_name":"PROCYSBI","family_id":"8d5dc6df320241e2b2bc","publication_number":"US9198882B2","cleaned_patent_number":"9198882","drug_product_flag":"-","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2027-07-26","publication_date":"2015-12-01","legal_status":"Granted"} US9198882B2 01 Dec, 2015 Granted 26 Jul, 2027
{"application_id":"43940","ingredient":"CYSTEAMINE BITARTRATE","trade_name":"PROCYSBI","family_id":"8d5dc6df320241e2b2bc","publication_number":"US9925156B2","cleaned_patent_number":"9925156","drug_product_flag":"-, Y","drug_substance_flag":"-, Y","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2027-07-26","publication_date":"2018-03-27","legal_status":"Granted"} US9925156B2 27 Mar, 2018 Granted 26 Jul, 2027
{"application_id":"43941","ingredient":"CYSTEAMINE BITARTRATE","trade_name":"PROCYSBI","family_id":"8d5dc6df320241e2b2bc","publication_number":"US9925157B2","cleaned_patent_number":"9925157","drug_product_flag":"-, Y","drug_substance_flag":"-, Y","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2027-07-26","publication_date":"2018-03-27","legal_status":"Granted"} US9925157B2 27 Mar, 2018 Granted 26 Jul, 2027
{"application_id":"43933","ingredient":"CYSTEAMINE BITARTRATE","trade_name":"PROCYSBI","family_id":"8d5dc6df320241e2b2bc","publication_number":"US8026284B2","cleaned_patent_number":"8026284","drug_product_flag":"-","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2028-03-22","publication_date":"2011-09-27","legal_status":"Granted"} US8026284B2 27 Sep, 2011 Granted 22 Mar, 2028
{"application_id":"43951","ingredient":"CYSTEAMINE BITARTRATE","trade_name":"PROCYSBI","family_id":"f1f9a8b156c345d7a8dc","publication_number":"US9233077B2","cleaned_patent_number":"9233077","drug_product_flag":"-, Y","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2034-12-17","publication_date":"2016-01-12","legal_status":"Granted"} US9233077B2 12 Jan, 2016 Granted 17 Dec, 2034
{"application_id":"43977","ingredient":"CYSTEAMINE BITARTRATE","trade_name":"PROCYSBI","family_id":"f1f9a8b156c345d7a8dc","publication_number":"US9173851B2","cleaned_patent_number":"9173851","drug_product_flag":"-, Y","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2034-12-17","publication_date":"2015-11-03","legal_status":"Granted"} US9173851B2 03 Nov, 2015 Granted 17 Dec, 2034
{"application_id":"43991","ingredient":"CYSTEAMINE BITARTRATE","trade_name":"PROCYSBI","family_id":"117e063c6ba74d939ba0","publication_number":"US10905662B2","cleaned_patent_number":"10905662","drug_product_flag":"-","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2037-02-16","publication_date":"2021-02-02","legal_status":"Granted"} US10905662B2 02 Feb, 2021 Granted 16 Feb, 2037
{"application_id":"43989","ingredient":"CYSTEAMINE BITARTRATE","trade_name":"PROCYSBI","family_id":"117e063c6ba74d939ba0","publication_number":"US10328037B2","cleaned_patent_number":"10328037","drug_product_flag":"-","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2037-02-16","publication_date":"2019-06-25","legal_status":"Granted"} US10328037B2 25 Jun, 2019 Granted 16 Feb, 2037
{"application_id":"43988","ingredient":"CYSTEAMINE BITARTRATE","trade_name":"PROCYSBI","family_id":"117e063c6ba74d939ba0","publication_number":"US10143665B2","cleaned_patent_number":"10143665","drug_product_flag":"-","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2037-02-16","publication_date":"2018-12-04","legal_status":"Granted"} US10143665B2 04 Dec, 2018 Granted 16 Feb, 2037
{"application_id":"43990","ingredient":"CYSTEAMINE BITARTRATE","trade_name":"PROCYSBI","family_id":"117e063c6ba74d939ba0","publication_number":"US10548859B2","cleaned_patent_number":"10548859","drug_product_flag":"-","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2037-02-16","publication_date":"2020-02-04","legal_status":"Granted"} US10548859B2 04 Feb, 2020 Granted 16 Feb, 2037

Recent Clinical Trials

Latest clinical trials and research studies for this ingredient

NCT ID Title Status Phase Conditions Start Date Completion Date

API Suppliers/Manufacturer (Branded/Generic companies)

Manufacturing Locations

View Complete Supplier List

Unlock access to all suppliers of Cysteamine Bitartrate

✓ Access a comprehensive list of global suppliers
✓ Get information on each supplier
Unlock Suppliers

Note: Patent expirations and exclusivity timelines are dynamic and may shift based on litigation, regulatory extensions, and maintenance filings. Regular monitoring is advised.

GreyB © 2025 Elixir. All rights reserved.